The demise of multidrug- resistant HIV-1: The national time trend in Portugal

Despite a decreasing mortality and morbidity in treated HIV-1 patients, highly active antiretroviral treatment (HAART) can still fail due to the development of drug resistance. Especially, multidrug-resistant viruses pose a threat to efficient therapy. We studied the changing prevalence of multidrug resistance (MDR) over time in a cohort of HIV-1-infected patients in Portugal.
Read More

Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving com- bination therapy including tenofovir

Authors: Abecasis AB, Abreu R, Aguas MJ, Aldir I, Aleixo MJ, Amaro G, Antunes F, Borges F, Botas J, Branco T, Caixas U, Camacho RJ, Diniz A, Doroana M, Duque L, Faria D, Faria N, Faria T, Fonseca P, Germano I, Gomes F, Guerreiro C, Jesus MB, Mansinho K, Mineiro A, Miranda AC, Narciso J, Neves I, Nina J, Pinheiro S, Pinto IV, Proença P, Reis AP, Roxo F, Sá J, Santos C, Snoeck J, Tavares L, Teófilo E, Theys K, Valadas E, Vandamme AM, Ventura F, Vera J, Vercauteren J
Journal: Journal of Antimicrobial Chemotherapy
Link: http://www.ncbi.nlm.nih.gov/pubmed/23027713

The use of tenofovir is highly associated with the emergence of mutation K65R, which confers broad resistance to nucleoside/nucleotide analogue reverse transcriptase inhibitors (NRTIs), especially when tenofovir is combined with other NRTIs also selecting for K65R. Although recent HIV-1 treatment guidelines discouraging these combinations resulted in reduced K65R selection with tenofovir, updated information on the impact of currently recommended regimens on the population selection rate of K65R is presently lacking.
Read More

The demise of multidrug- resistant HIV-1: The national time trend in Portugal

Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving com- bination therapy including tenofovir

About GHTM

Contacts

Map